The goal of an ongoing pivotal phase 3 trial in mild and moderate AD (NCT04669028) that began in May 2021 is to see if NE3107's impact on inflammation and insulin resistance will help slow the rate of cognitive loss. The gene discussed is INS; the disease is Alzheimer disease.